Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

10362	Companies
215714	Keywords
145484	Articles
114249	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 06/25/2024 at 23:00, 1 year 10 months ago

RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024
Biophytis SA announces the approval of all resolutions at the combined general meeting held on June 24, 2024, with significant shareholder participation

Shareholders General Meeting Resolutions Approval Biophytis SA
BRIEF

published on 06/20/2024 at 07:05, 1 year 10 months ago

Biophytis Grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at Up to €108 Million

Biophytis Pharmaceuticals Latin America BIO101 Blanver
PRESS RELEASE

published on 06/20/2024 at 07:00, 1 year 10 months ago

Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 million. Agreement includes upfront and milestones payments, double-digit royalties, and collaboration on manufacturing and clinical development

Biophytis Latin America Exclusive Rights Blanver Pharmaceutical Deal
REGULATED PRESS RELEASE

published on 06/20/2024 at 07:00, 1 year 10 months ago

Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million. Collaboration for commercialization and clinical development announced

Biophytis Latin America BIO101 Exclusive Rights Blanver
BRIEF

published on 06/20/2024 at 01:15, 1 year 10 months ago

Biophytis extends its contract with Atlas to finance its clinical activities

Biophytis Biotechnology Convertible Bonds Funding Atlas
PRESS RELEASE

published on 06/20/2024 at 01:10, 1 year 10 months ago

Biophytis extends its contract with Atlas to secure financing for its business activities
Biophytis extends financing agreement with Atlas, ensures funding for clinical programs OBA in obesity and MYODA in DMD. Details on the contract amendment and risk factors

Biophytis Atlas Financing Agreement Clinical Programs Risk Factors
BRIEF

published on 06/19/2024 at 23:05, 1 year 10 months ago

Biophytis Extends Financing Contract with Atlas

Biophytis Biotechnology Financing Clinical Trials Atlas
REGULATED PRESS RELEASE

published on 06/19/2024 at 23:00, 1 year 10 months ago

Biophytis extends its contract with Atlas to secure financing for its business activities
Biophytis extends bond financing agreement with Atlas, securing funding for clinical programs in obesity and Duchenne Muscular Dystrophy. Terms reflect confidence in growth potential

Biophytis Atlas Growth Potential Clinical Programs Bond Financing Agreement
BRIEF

published on 06/12/2024 at 10:16, 1 year 10 months ago

Biophytis announces the success of the industrial transfer of production of BIO101

Biophytis Biotechnology Duchenne Muscular Dystrophy BIO101 Seqens
PRESS RELEASE

published on 06/12/2024 at 10:11, 1 year 10 months ago

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens
Biophytis successfully transfers BIO101 (20-hydroxyecdysone) production to industrial scale with Seqens, enhancing therapeutic solutions for Duchenne Muscular Dystrophy patients

Biophytis Duchenne Muscular Dystrophy BIO101 Seqens 20-hydroxyecdysone

Accesswire

Published on 05/07/2026 at 09:05, 1 hour 17 minutes ago

Nano One Appoints Jason Zandberg as Director of Capital Markets
Published on 05/07/2026 at 05:40, 4 hours 42 minutes ago

New Horizon Aircraft Ltd. Announces Pricing of $20 Million Offering of Common Shares
Published on 05/07/2026 at 02:00, 8 hours 22 minutes ago

Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
Published on 05/06/2026 at 23:30, 10 hours 52 minutes ago

Stabilis Solutions Announces First Quarter 2026 Results
Published on 05/06/2026 at 23:05, 11 hours 17 minutes ago

Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity

View all ACCESSWIRE

EQS Group

Published on 05/07/2026 at 10:00, 22 minutes ago

Mirah Investment & Development Announces Strategic Partnership with RV Capital Across Portfolio of Hospitality Brands
Published on 05/07/2026 at 10:00, 22 minutes ago

Invitation to the 19th International Investment Forum (IIF) on May 20, 2026 – Digital Focus on Global Growth Stocks
Published on 05/07/2026 at 09:46, 36 minutes ago

EQS-Adhoc: Deutsche Bank to issue Additional Tier 1 capital instruments
Published on 05/07/2026 at 09:30, 52 minutes ago

Encavis acquires 80‑megawatt Vietlübbe wind farm in Germany
Published on 05/07/2026 at 09:05, 1 hour 17 minutes ago

MSI IPC Launches Quad-Display MS-C936 Slim Box PC and High-Connectivity MS-CF27 SBC for Industrial Edge Computing

Les Echos

Published on 05/07/2026 at 07:43, 2 hours 39 minutes ago

ENGIE - Q1 2026 financial information
Published on 05/06/2026 at 18:00, 16 hours 22 minutes ago

Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026
Published on 05/06/2026 at 18:00, 16 hours 22 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of April 30, 2026
Published on 05/06/2026 at 17:45, 16 hours 37 minutes ago

Information concerning the total number of voting rights and shares 2026 04 30
Published on 05/06/2026 at 17:45, 16 hours 37 minutes ago

Declaration of voting rights at the end of April 2026

View all LES ECHOS COMFI WIRE